MACK logo

MACK Cash From Operations

MACK Annual CFO

-$1.52 M
+$220.00 K+12.63%

31 December 2023

1-Year Change

+12.63%
MACK annual cash flow from operations is up +12.63% year-on-year

3-Year Change

+67.09%
MACK annual cash flow from operations is up +67.09% over the past 3 years

All-time High

$19.05 M
MACK annual cash flow from operations is currently -107.99% below its historical high of $19.05 million

Annual CFO Formula

Net Income + Non Cash Expenses + Changes In Working Capital
Annual CFI-$12.45 M
MACK annual cash flow from investing activities is -$12.45 million
Annual CFF$521.00 K
MACK annual cash flow from financing activities is $521.00 thousand
Annual FCF-$1.52 M
MACK annual free cash flow is -$1.52 million

MACK Cash From Operations Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

MACK Quarterly CFO

-$1.31 M
-$1.02 M-345.42%

01 March 2024

1-Year Change

-547.29%
MACK quarterly cash flow from operations is down -547.29% year-on-year

3-Year Change

-547.29%
MACK quarterly cash flow from operations is down -547.29% over the past 3 years

All-time High

$61.10 M
MACK quarterly cash flow from operations is currently -102.15% below its historical high of $61.10 million
Quarterly CFI$228.00 M
MACK quarterly cash flow from investing activities is $228.00 million
Quarterly CFF$1.49 M
MACK quarterly cash flow from financing activities is $1.49 million
Quarterly FCF-$1.31 M
MACK quarterly free cash flow is -$1.31 million

MACK Quarterly CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

MACK TTM CFO

-$2.48 M
-$958.00 K-62.94%

01 March 2024

1-Year Change

-75.64%
MACK TTM cash flow from operations is down -75.64% year-on-year

3-Year Change

-75.64%
MACK TTM cash flow from operations is down -75.64% over the past 3 years

All-time High

-$135.00 K
TTM CFI$215.41 M
MACK TTM cash flow from investing activities is $215.41 million
TTM CFF$1.83 M
MACK TTM cash flow from financing activities is $1.83 million
TTM FCF-$2.48 M
MACK TTM free cash flow is -$2.48 million

MACK TTM CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

MACK Cash From Operations Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+12.6%-547.3%-75.6%
3 y3 years+67.1%-547.3%-75.6%
5 y5 years+97.7%-547.3%-75.6%

MACK Cash From Operations High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year
5 y5-year
alltimeall time-108.0%-102.2%+1737.0%

Merrimack Pharmaceuticals Cash From Operations History

DateAnnualQuarterlyTTM
Mar 2024
-
-$1.31 M(+345.4%)
-$2.48 M(+62.9%)
Dec 2023
-$1.52 M(-12.6%)
-$295.00 K(+45.3%)
-$1.52 M(+7.8%)
Sept 2023
-
-$203.00 K(-69.6%)
-$1.41 M(-4.1%)
June 2023
-
-$668.00 K(+87.6%)
-$1.47 M(-15.5%)
Mar 2023
-
-$356.00 K(+92.4%)
-$1.74 M(+0.1%)
Dec 2022
-$1.74 M(+699.1%)
-$185.00 K(-29.9%)
-$1.74 M(-8.9%)
Sept 2022
-
-$264.00 K(-71.9%)
-$1.91 M(-8.6%)
June 2022
-
-$939.00 K(+165.3%)
-$2.09 M(+1450.4%)
Mar 2022
-
-$354.00 K(-0.3%)
-$135.00 K(-38.1%)
Dec 2021
-$218.00 K(-95.3%)
-$355.00 K(-20.2%)
-$218.00 K(-86.7%)
Sept 2021
-
-$445.00 K(-143.7%)
-$1.64 M(+54.8%)
June 2021
-
$1.02 M(-333.2%)
-$1.06 M(-73.9%)
Mar 2021
-
-$437.00 K(-75.4%)
-$4.06 M(-12.3%)
Dec 2020
-$4.63 M(-85.3%)
-$1.78 M(-1415.6%)
-$4.63 M(-15.7%)
Sept 2020
-
$135.00 K(-106.8%)
-$5.49 M(-37.8%)
June 2020
-
-$1.98 M(+96.9%)
-$8.83 M(-52.8%)
Mar 2020
-
-$1.00 M(-61.9%)
-$18.72 M(-40.3%)
Dec 2019
-$31.37 M(-52.2%)
-$2.64 M(-17.6%)
-$31.37 M(-34.1%)
Sept 2019
-
-$3.20 M(-73.0%)
-$47.62 M(-17.2%)
June 2019
-
-$11.87 M(-13.0%)
-$57.53 M(-7.1%)
Mar 2019
-
-$13.65 M(-27.7%)
-$61.90 M(-5.6%)
Dec 2018
-$65.59 M(-47.9%)
-$18.89 M(+44.1%)
-$65.59 M(-8.3%)
Sept 2018
-
-$13.11 M(-19.3%)
-$71.49 M(-14.9%)
June 2018
-
-$16.24 M(-6.3%)
-$84.01 M(-36.8%)
Mar 2018
-
-$17.34 M(-30.1%)
-$132.99 M(+5.7%)
Dec 2017
-$125.81 M(-26.1%)
-$24.79 M(-3.3%)
-$125.81 M(-4.6%)
Sept 2017
-
-$25.64 M(-60.7%)
-$131.92 M(-6.6%)
June 2017
-
-$65.23 M(+542.3%)
-$141.20 M(+11.3%)
Mar 2017
-
-$10.16 M(-67.1%)
-$126.87 M(-25.5%)
DateAnnualQuarterlyTTM
Dec 2016
-$170.24 M(+61.6%)
-$30.90 M(-11.5%)
-$170.24 M(+19.3%)
Sept 2016
-
-$34.92 M(-31.4%)
-$142.65 M(-5.0%)
June 2016
-
-$50.90 M(-4.9%)
-$150.13 M(+21.3%)
Mar 2016
-
-$53.52 M(+1518.0%)
-$123.80 M(+17.5%)
Dec 2015
-$105.36 M(+202.7%)
-$3.31 M(-92.2%)
-$105.36 M(-21.2%)
Sept 2015
-
-$42.39 M(+72.5%)
-$133.73 M(+342.2%)
June 2015
-
-$24.58 M(-29.9%)
-$30.25 M(-21.4%)
Mar 2015
-
-$35.08 M(+10.7%)
-$38.50 M(+10.6%)
Dec 2014
-$34.81 M(-63.4%)
-$31.68 M(-151.9%)
-$34.81 M(+13.9%)
Sept 2014
-
$61.10 M(-286.1%)
-$30.55 M(-73.2%)
June 2014
-
-$32.83 M(+4.6%)
-$113.97 M(+8.2%)
Mar 2014
-
-$31.39 M(+14.4%)
-$105.37 M(+10.7%)
Dec 2013
-$95.17 M(+19.2%)
-$27.43 M(+22.9%)
-$95.17 M(+9.2%)
Sept 2013
-
-$22.32 M(-7.9%)
-$87.18 M(+2.8%)
June 2013
-
-$24.23 M(+14.3%)
-$84.80 M(+3.9%)
Mar 2013
-
-$21.20 M(+9.1%)
-$81.61 M(+2.2%)
Dec 2012
-$79.82 M(+51.1%)
-$19.43 M(-2.5%)
-$79.82 M(+19.4%)
Sept 2012
-
-$19.94 M(-5.2%)
-$66.84 M(+6.2%)
June 2012
-
-$21.04 M(+8.4%)
-$62.91 M(+1.0%)
Mar 2012
-
-$19.40 M(+200.6%)
-$62.28 M(+17.9%)
Dec 2011
-$52.82 M(+100.3%)
-$6.46 M(-59.7%)
-$52.82 M(+0.9%)
Sept 2011
-
-$16.02 M(-21.5%)
-$52.34 M(+58.7%)
June 2011
-
-$20.40 M(+105.2%)
-$32.98 M(+47.3%)
Mar 2011
-
-$9.94 M(+66.3%)
-$22.39 M(-15.1%)
Dec 2010
-$26.37 M(-238.4%)
-$5.98 M(-278.7%)
-$26.37 M(+29.3%)
Sept 2010
-
$3.35 M(-134.1%)
-$20.39 M(-14.1%)
June 2010
-
-$9.81 M(-29.6%)
-$23.73 M(+70.4%)
Mar 2010
-
-$13.93 M
-$13.93 M
Dec 2009
$19.05 M
-
-

FAQ

  • What is Merrimack Pharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Merrimack Pharmaceuticals?
  • What is Merrimack Pharmaceuticals annual CFO year-on-year change?
  • What is Merrimack Pharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Merrimack Pharmaceuticals?
  • What is Merrimack Pharmaceuticals quarterly CFO year-on-year change?
  • What is Merrimack Pharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Merrimack Pharmaceuticals?
  • What is Merrimack Pharmaceuticals TTM CFO year-on-year change?

What is Merrimack Pharmaceuticals annual cash flow from operations?

The current annual CFO of MACK is -$1.52 M

What is the all time high annual CFO for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals all-time high annual cash flow from operations is $19.05 M

What is Merrimack Pharmaceuticals annual CFO year-on-year change?

Over the past year, MACK annual cash flow from operations has changed by +$220.00 K (+12.63%)

What is Merrimack Pharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of MACK is -$1.31 M

What is the all time high quarterly CFO for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals all-time high quarterly cash flow from operations is $61.10 M

What is Merrimack Pharmaceuticals quarterly CFO year-on-year change?

Over the past year, MACK quarterly cash flow from operations has changed by -$1.11 M (-547.29%)

What is Merrimack Pharmaceuticals TTM cash flow from operations?

The current TTM CFO of MACK is -$2.48 M

What is the all time high TTM CFO for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals all-time high TTM cash flow from operations is -$135.00 K

What is Merrimack Pharmaceuticals TTM CFO year-on-year change?

Over the past year, MACK TTM cash flow from operations has changed by -$1.07 M (-75.64%)